Ropinirole
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Ropinirole
- Ropinirole: From Parkinson’s Disease and Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
Ropinirole: From Parkinson’s Disease and Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Ropinirole is a dopamine agonist. It is generally used for Parkinson’s disease and restless legs syndrome (RLS), and it is registered in South Africa as an oral tablet. The TxGNN model predicts it may be useful for attention deficit-hyperactivity disorder (ADHD). No clinical trials support this. The evidence is 1 narrative review and 1 single-patient case report, and the case report treated RLS in a child who also had ADHD.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration records provided. Ropinirole is generally used for Parkinson’s disease and RLS. |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ropinirole is a non-ergot D2/D3 dopamine agonist. Detailed mechanism-of-action data were not available in the record, so this description comes from the literature and general pharmacology.
The link to ADHD runs through RLS. RLS and ADHD often occur together, and both are hypothesised to involve dopaminergic dysfunction and altered iron metabolism. A 2005 review examined this association and discussed whether common treatments might serve both conditions when they co-occur.
The only direct clinical observation is a 2005 case report. A 6-year-old boy with ADHD, poorly controlled on methylphenidate, also had RLS or periodic limb movements. Ropinirole improved both his sleep and his ADHD symptoms. This is one patient with a comorbid condition, so it cannot show that ropinirole treats core ADHD symptoms. The very high TxGNN score is a model output, not clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16218085 | 2005 | Review | Sleep | Reviews the association between RLS and ADHD, the possible shared mechanisms, and the potential for common treatments when both occur. |
| 18656214 | 2008 | Review | Revue neurologique | General review of RLS. It is background only and does not test ropinirole in ADHD. |
| 15866437 | 2005 | Case report | Pediatric Neurology | A child with ADHD and RLS improved in both ADHD symptoms and sleep on ropinirole. |
| 34182128 | 2021 | Preclinical (in vitro) | Pharmacological Research | Dopamine D4 receptor variants and α2A adrenoceptors form receptor complexes. This is relevant to impulse-control disorders and ADHD biology, but it does not test ropinirole. |
| 17483695 | 2007 | Preclinical (animal) | J Neuropathol Exp Neurol | A mouse model of RLS based on dopamine and iron dysfunction. It is indirect support for the shared-mechanism idea. |
| 24992083 | 2014 | Clinical study | Clin Neuropharmacol | Compares piribedil with pramipexole and ropinirole for daytime sleepiness in Parkinson’s disease. It is not relevant to ADHD efficacy. |
| 30950895 | 2019 | Case series (safety) | Cornea | Reports corneal oedema associated with systemic dopaminergic agents. |
| 30460371 | 2019 | Case report (safety) | Acta Dermato-Venereologica | Reports treatment-induced delusions of infestation linked to increased brain dopamine. |
South Africa Market Information
Ropinirole has 2 SAHPRA registrations, both oral tablets. The records provided do not include manufacturer or approved-indication text. Essential Medicines List (EML) status was not included in the data.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 43/5.4.1/0216 | Resure 0.25 Tablets | Tablet |
| Reg. No. 31/5.4.1/0301 | Requip 0.25 | Tablet |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
The retrieved literature also describes safety signals for dopamine agonists. These include corneal oedema, delusions and psychotic symptoms, and impulse-control problems such as gambling. They matter most in a paediatric or neuropsychiatric setting. No drug-interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The ADHD prediction rests on a model score, a narrative review and a single comorbid case report. There are no registered trials, no evidence of benefit for core ADHD symptoms, and no SAHPRA safety data have been reviewed. The other nine TxGNN predictions have even less support. Most have no evidence at all, and the ophthalmic hits appear to be keyword noise. For schizophrenia the evidence is indirect, and dopamine agonists carry a known risk of psychosis, so the safety signal is unfavourable.
To proceed, the following is needed:
- SAHPRA package insert warnings and contraindications, which are needed before any safety screening
- Mechanism-of-action data, for example from DrugBank
- Controlled evidence in ADHD, ideally in patients with comorbid RLS or sleep-related movement disorders, to separate an effect on RLS from an effect on ADHD
- A paediatric safety assessment, including psychiatric and impulse-control adverse effects
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.